Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

IntroductionAngiotensin converting-enzyme 2 (ACE2) is an enzyme catalyzing the conversion of angiotensin 2 into angiotensin 1-7. ACE2 also serves as the receptor of several coronaviruses, including SARS-CoV-1 and SARS-CoV-2. Therefore, ACE2 could be utilized as a therapeutic target for treating thes...

Full description

Bibliographic Details
Main Authors: Shengjiang Liu, Haifeng Chen, Xiangqun Chen, Ningguang Luo, Sameera Peraramelli, Xiaoming Gong, Mingwei John Zhang, Li Ou
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
COVID-19
SARS-CoV-2
ACE2
neutralization
protein engineering
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1365803/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1365803/full

Similar Items